Published in Vaccine Weekly, June 22nd, 2005
The ongoing findings of this trial indicate that vaccine therapy is generally well tolerated and may reduce residual leukemic cells that persist after chemotherapy, as indicated by decreased levels of WT-1, a leukemia-associated genetic marker, which is detectable in over 95% of patients with active AML.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly